Visualization firms invest in TeraRecon
Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal
Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal in March; Pentax signed its agreement in May. Both agreements were announced earlier this month. Fujifilm paid $4.95 million to acquire 300,000 shares of newly issued series G preferred stock, representing a 1.92% equity stake in TeraRecon. Under the terms of the alliance, TeraRecon will apply its signal and image processing technologies to new product and technology development at Fuji. Pentax paid $5.67 million to acquire 341,000 shares of newly issued series G preferred stock, representing 2.18% of issued equity. In return, Pentax has the right to include TeraRecon technology in products such as those involving optical endoscopic imaging and consumer electronics digital camera applications.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
